National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (2018) https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 10 Nov 2018
Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918–26. https://doi.org/10.1001/jama.2017.11470.
Article
PubMed
PubMed Central
Google Scholar
Cools-Lartigue J, Sinclair A, Trabulsi N, Meguerditchian A, Mesurolle B, Fuhrer R, et al. Preoperative axillary ultrasound and fine-needle aspiration biopsy in the diagnosis of axillary metastases in patients with breast cancer: predictors of accuracy and future implications. Ann Surg Oncol. 2013;20(3):819–27. https://doi.org/10.1245/s10434-012-2609-7.
Article
PubMed
Google Scholar
del Riego J, Diaz-Ruiz MJ, Teixido M, Ribe J, Vilagran M, Canales L, et al. The impact of preoperative axillary ultrasonography in T1 breast tumours. Eur Radiol. 2016;26(4):1073–81. https://doi.org/10.1007/s00330-015-3901-2.
Article
PubMed
Google Scholar
Farshid G, Kollias J, Grantley Gill P. The clinical utility of assessment of the axilla in women with suspicious screen detected breast lesions in the post Z0011 era. Breast Cancer Res Treat. 2015;151(2):347–55. https://doi.org/10.1007/s10549-015-3388-1.
Article
PubMed
Google Scholar
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305. https://doi.org/10.1016/S1470-2045(13)70035-4.
Article
PubMed
PubMed Central
Google Scholar
Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32. (discussion 32-3. doi:10.1097/SLA.0b013e3181f08f32)
PubMed
PubMed Central
Google Scholar
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10. https://doi.org/10.1016/S1470-2045(14)70460-7.
Article
PubMed
PubMed Central
Google Scholar
Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(18):2946–53. https://doi.org/10.1200/JCO.2008.19.5750.
Article
Google Scholar
Fant JS, Grant MD, Knox SM, Livingston SA, Ridl K, Jones RC, et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol. 2003;10(2):126–30.
Article
Google Scholar
Pilewskie M, Morrow M. Reply to "Implications of abnormal preoperative axillary imaging in the post Z011 era". Gland surgery. 2016;5(4):453–4. https://doi.org/10.21037/gs.2016.07.03.
Article
PubMed
PubMed Central
Google Scholar
Lim GH, Upadhyaya VS, Acosta HA, Lim JMA, Allen JC Jr, Leong LCH. Preoperative predictors of high and low axillary nodal burden in Z0011 eligible breast cancer patients with a positive lymph node needle biopsy result. Eur J Surg Oncol. 2018;44(7):945–50. https://doi.org/10.1016/j.ejso.2018.04.003.
Article
PubMed
Google Scholar
Hieken TJ, Trull BC, Boughey JC, Jones KN, Reynolds CA, Shah SS, et al. Preoperative axillary imaging with percutaneous lymph node biopsy is valuable in the contemporary management of patients with breast cancer. Surgery. 2013;154(4):831–8. (discussion 8-40. doi:10.1016/j.surg.2013.07.017).
Article
Google Scholar
Pilewskie M, Mautner SK, Stempel M, Eaton A, Morrow M. Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era? Ann Surg Oncol. 2016;23(4):1123–8. https://doi.org/10.1245/s10434-015-4944-y.
Article
PubMed
Google Scholar
Zhu Y, Zhou W, Zhou JQ, Fei XC, Ye TJ, Huang O, et al. Axillary staging of early-stage invasive breast cancer by ultrasound-guided fine-needle aspiration cytology: which ultrasound criteria for classifying abnormal lymph nodes should be adopted in the post-ACOSOG Z0011 trial Era? J Ultrasound Med. 2016;35(5):885–93. https://doi.org/10.7863/ultra.15.06019.
Article
PubMed
Google Scholar
Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133(3):831–41. https://doi.org/10.1007/s10549-011-1891-6.
Article
PubMed
Google Scholar
Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26(14):2373–8. https://doi.org/10.1200/JCO.2007.14.4287.
Article
PubMed
Google Scholar
Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, Hunt KK, et al. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancesr Res BCR. 2012;14(3):R82. https://doi.org/10.1186/bcr3197.
Article
Google Scholar
Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684–91. https://doi.org/10.1200/JCO.2009.24.9284.
Article
PubMed
Google Scholar
Holm-rasmussen EV, Jensen MB, Balslev E, et al. Reduced risk of axillary lymphatic spread in triple-negative breast cancer. Breast Cancer Res Treatment 2015, 149(1): 229–36. dio: 10.1007/s10549–014–3225-y
Article
Google Scholar
Freedman GM, Anderson PR, Li T, et al. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 2009;115(5):946–51. https://doi.org/10.1002/cncr.24094.
Article
PubMed
PubMed Central
Google Scholar
Crabb SJ, Cheang MC, Leung S, et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clinical Breast Cancer. 2008;8(3):249–56. https://doi.org/10.3816/cbc.2008.n.028.
Article
PubMed
Google Scholar
Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115(2):423–8. https://doi.org/10.1007/s10549-008-0086-2.
Article
PubMed
Google Scholar
Caudle AS, Kuerer HM, Le-Petross HT, Yang W, Yi M, Bedrosian I, et al. Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol. 2014;21(11):3440–7. https://doi.org/10.1245/s10434-014-3813-4.
Article
PubMed
Google Scholar
Morrow M, Van Zee KJ, Patil S, Petruolo O, Mamtani A, Barrio AV, et al. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients. Ann Surg. 2017;266(3):457–62. https://doi.org/10.1097/SLA.0000000000002354.
Article
PubMed
PubMed Central
Google Scholar